FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (HSP90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
The invention provides methods for treating HIF-1α-overexpressing human tumors, inhibiting HIF-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90α from the tumors.
1 . An isolated peptide comprising the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
2 . A nucleic acid molecule encoding the peptide of claim 1 .
3 . A cDNA molecule of claim 2 .
4 . A vector comprising the cDNA molecule of claim 3 .
5 . A host-vector system comprising the vector of claim 4 transfected into a compatible host cell.
6 . The host-vector system of claim 5 , wherein the compatible host cell is a prokaryotic cell or a eukaryotic cell.
7 . An antibody which recognizes and binds an epitope comprising the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and/or SEQ ID NO: 6.
8 . The antibody of claim 7 , wherein the antibody is a monoclonal antibody or fragment thereof, a polyclonal antibody or a fragment thereof, chimeric antibodies, humanized antibodies, human antibodies, or a single chain antibody.
9 . A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutical carrier.
10 . A vaccine comprising the isolated peptide of claim 1 .
11 . A method for treating HIF-1α-overexpressing cancer in a subject in need thereof comprising:
(a) providing a composition comprising an inhibitor of Hsp90α; and
(b) administering a therapeutically effective amount of the composition to the subject so as to treat HIF-1-positive cancer in the subject.
12 . (canceled)
13 . (canceled)
14 . The method of claim 11 , wherein the inhibitor of Hsp90α targets the amino acids of Hsp90α as set forth in SEQ ID NO: 3, SEQ ID NO: 4,
SEQ ID NO: 5 and/or SEQ ID NO:6.
15 . The method of claim 11 , wherein the inhibitor of Hsp90α is selected from the group consisting of a small molecule, a peptide, an antibody or a fragment thereof and a nucleic acid molecule.
16 . The method of claim 11 , wherein the inhibitor of Hsp90α is an inhibitor of Hsp90α eceptor and is selected from the group consisting of a small molecule, a peptide, an antibody or a fragment thereof or a nucleic acid molecule.
17 . The method of claim 15 , wherein the nucleic acid molecule is a siRNA molecule.
18 . The method of claim 15 , wherein the antibody is selected from the group consisting of monoclonal antibody or fragment thereof, a polyclonal antibody or a fragment thereof, chimeric antibodies, humanized antibodies, human antibodies, and a single chain antibody.
19 - 29 . (canceled)